Boston-based immuno-oncology company Vor Biopharma has fetched $42 million in Series A financing.
The round was spearheaded by California-based venture capital firm 5AM Ventures and multi-stage investment manager RA Capital Management.
Other backers including Johnson & Johnson Development Corp, an arm of U.S. drugmaker Johnson & Johnson, Novartis Institutes for BioMedical Research, and Osage University Partners also joined the round.
With the net capital raised, Vor will advance its lead hematopoietic stem cell-based candidates for the treatment of acute myeloid leukaemia towards the clinic and further build its pipeline to treat hematologic malignancies.